<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001233.v1.p1" parentStudy="phs001233.v1.p1" createDate="2016-10-21" modDate="2016-11-28">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Lorenz Studer</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Nadja Zeltner</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Disease Severity in Familial Dysautonomia</StudyNameEntrez>
	<StudyNameReportPage>Disease Severity in Familial Dysautonomia</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Familial Dysautonomia (FD) is a developmental and degenerative genetic disease that manifests in the neural crest cells and peripheral nervous system (PNS). Despite all FD patients having the same mutation in <i>IKBKAP</i>, patients present with varying disease severity, ranging from mild to severe. We used the human pluripotent stem cell technology to recapitulate this varying disease severity in the dish. Further, we found that severe, but not mild patients harbor mutations in candidate modifier genes that may contribute to severe disease presentation.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="27841875"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Dysautonomia, Familial"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Lorenz Studer</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Nadja Zeltner</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>Fibroblast patient samples were purchased from Coriell Biorepository. The patients were selected based on the accompanying clinical description of symptoms on the Coriell Biorepository website and categorized by us into mild FD or severe FD patient groups.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-FDY-COL" longName="Disease-Specific (Familial Dysautonomia, COL)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NINDS</DacName>
      <DacFullName>National Institute of Neurological Disorders and Stroke</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001233.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001233.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001233.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Familial Dysautonomia, COL)</ConsentName>
        <ConsentAbbrev>DS-FDY-COL</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Familial Dysautonomia.
Requestor must provide a letter of collaboration with the primary study investigator(s).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
